Value of TRAcP 5b as a diagnostic marker for detection of bone metastases in patients with breast cancer.
The aim of the study was to test the bone resorption marker TRAcP 5b regarding its suitability for detection of bone metastases in breast cancer patients. Serum samples from a total of 101 patients with histologically proven breast cancer and from 100 healthy probands were analyzed. The patients were divided into three groups: eight patients without osseous involvement, 65 patients with untreated bone metastases, 28 patients whose bone metastases were treated with bisphosphonate therapy. The TRAcP 5b concentration was significantly higher in breast cancer patients compared to healthy probands. It was not possible to demonstrate a statistically significant difference in the TRAcP 5b concentration if osseous metastases in breast cancer patients were present or not. Our research cannot support the claim that TRAcP 5b could be useful as a diagnostic tool for the detection of bone metastases in patients with breast cancer.